TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Industry, Sector and Symbol:
- Market Cap: $1.04 million
- Outstanding Shares: 24,769,000
- 50 Day Moving Avg: $0.04
- 200 Day Moving Avg: $0.06
- 52 Week Range: $0.03 - $0.50
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.04
- P/E Growth: 0.000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($1.25) per share
- Price / Book: -0.03
- EBIDTA: ($21,140,000.00)
- Return on Assets: -81.56%
- Debt-to-Equity Ratio: -1.00%
- Current Ratio: 0.48%
- Quick Ratio: 0.48%
- Average Volume: 82,300 shs.
- Beta: 3
- Short Ratio: 4.39
Frequently Asked Questions for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
What is Tetralogic Pharmaceuticals Corp's stock symbol?
Tetralogic Pharmaceuticals Corp trades on the NASDAQ under the ticker symbol "TLOG."
How were Tetralogic Pharmaceuticals Corp's earnings last quarter?
Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) released its quarterly earnings results on Thursday, February, 26th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.14. View Tetralogic Pharmaceuticals Corp's Earnings History.
Who are some of Tetralogic Pharmaceuticals Corp's key competitors?
Some companies that are related to Tetralogic Pharmaceuticals Corp include Affymax (AFFY), Aegerion Pharmaceuticals (AEGR), Anacor Pharmaceuticals (ANAC), Ariad Pharmaceuticals (ARIA), Baxalta (BXLT), Biotie Therapies Corp (BITI), Caladrius Biosciences (CLBS), CoLucid Pharmaceuticals (CLCD), Cubist Pharmaceuticals (CBST), Cynapsus Therapeutics (CYNA), DARA Biosciences (DARA), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Dyax Corp. (DYAX), Epirus Biopharmaceuticals (EPRS), Horizon Therapeutics (HPTX) and Idenix Pharmaceuticals (IDIX).
How do I buy Tetralogic Pharmaceuticals Corp stock?
Shares of Tetralogic Pharmaceuticals Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Tetralogic Pharmaceuticals Corp stock cost?
One share of Tetralogic Pharmaceuticals Corp stock can currently be purchased for approximately $0.04.
Consensus Ratings for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
(Data available from 5/27/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/7/2016||Roth Capital||Lower Price Target||Buy||$5.00 -> $1.00||N/A|
Earnings History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)Earnings History by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Current Year EPS Consensus Estimate: $-1.770 EPS
Next Year EPS Consensus Estimate: $-0.990 EPS
Dividend History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Insider Ownership Percentage: 24.00%Insider Trades by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Institutional Ownership Percentage: 2.69%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/9/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||333,630||$0.17||$56,717.10|| |
|2/5/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||1,415,490||$0.18||$254,788.20|| |
|2/2/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||369,132||$0.19||$70,135.08|| |
|1/28/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||311,930||$0.28||$87,340.40|| |
|7/10/2015||Andrew L Pecora||Director||Buy||50,000||$2.68||$134,000.00|| |
|7/9/2015||Andrew L Pecora||Director||Buy||50,000||$2.40||$120,000.00|| |
|7/2/2015||Paul J Schmitt||Director||Buy||10,000||$2.34||$23,400.00|| |
|3/27/2015||Pete A Meyers||CFO||Buy||5,000||$4.35||$21,750.00|| |
|3/26/2015||J Kevin Buchi||CEO||Buy||5,000||$4.23||$21,150.00|| |
|1/7/2015||J Kevin Buchi||CEO||Buy||5,000||$5.04||$25,200.00|| |
|12/10/2014||Colin Glenn Begley||SVP||Buy||5,900||$6.16||$36,344.00|| |
|12/9/2014||J Kevin Buchi||CEO||Buy||5,000||$6.01||$30,050.00|| |
|12/4/2014||Pete A Meyers||CFO||Buy||1,034||$4.94||$5,107.96|| |
|12/2/2014||J Kevin Buchi||CEO||Buy||10,000||$4.99||$49,900.00|| |
|11/26/2014||Colin Glenn Begley||SVP||Buy||3,100||$4.86||$15,066.00|| |
|11/26/2014||Lesley Russell||COO||Buy||20,000||$4.90||$98,000.00|| |
|11/25/2014||Colin Glenn Begley||SVP||Buy||2,000||$4.85||$9,700.00|| |
|11/18/2014||J Kevin Buchi||CEO||Buy||10,000||$4.82||$48,200.00|| |
|11/17/2014||Andrew L Pecora||Director||Buy||20,000||$4.53||$90,600.00|| |
|11/12/2014||Peter A Meyers||CFO||Buy||5,000||$3.98||$19,900.00|| |
|11/11/2014||J Kevin Buchi||CEO||Buy||10,000||$3.93||$39,300.00|| |
|11/10/2014||Paul J Schmitt||Director||Buy||20,000||$4.10||$82,000.00|| |
|12/17/2013||J Kevin Buchi||CEO||Buy||285,714||$7.00||$1,999,998.00|| |
|12/17/2013||James N Woody||Director||Buy||261,427||$7.00||$1,829,989.00|| |
|12/17/2013||Peter A Meyers||CFO||Buy||142,857||$7.00||$999,999.00|| |
|12/17/2013||Ventures Vii Lp Healthcare||Major Shareholder||Buy||713,463||$7.00||$4,994,241.00|| |
Headline Trends for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Latest Headlines for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Tetralogic Pharmaceuticals Corp (TLOG) Chart for Saturday, May, 27, 2017